NAS:DOVA (USA) Also trade in: Germany

Dova Pharmaceuticals Inc

$ 9.06 -0.19 (-2.05%)
Volume: 111,353 Avg Vol (1m): 139,820
Market Cap $: 258.33 Mil Enterprise Value $: 186.47 Mil
P/E (TTM): 0.00 P/B: 4.07
Earnings Power Value 0
Net Current Asset Value 2.18
Tangible Book 2.24
Projected FCF 0
Median P/S Value 20.52
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 5/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 4.45
Cash-To-Debt ranked higher than
62.24% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
DOVA: 4.45
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 1, Med: 4.08, Max: 10000
Current: 4.45
1
10000
Equity-to-Asset 0.63
Equity-to-Asset ranked lower than
100.00% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
DOVA: 0.63
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.63, Med: 0.7, Max: 0.78
Current: 0.63
0.63
0.78
Debt-to-Equity 0.33
Debt-to-Equity ranked lower than
100.00% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
DOVA: 0.33
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -7.06, Med: 0.33, Max: 14.98
Current: 0.33
-7.06
14.98
Debt-to-EBITDA -0.29
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
DOVA: -0.29
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -1.05, Med: -0.67, Max: -0.29
Current: -0.29
-1.05
-0.29
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0.58
DISTRESS
GREY
SAFE

Profitability & Growth : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -513.56
Operating Margin ranked lower than
100.00% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
DOVA: -513.56
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -686.14, Med: -686.14, Max: -513.56
Current: -513.56
-686.14
-513.56
Net Margin % -521.68
Net Margin ranked lower than
100.00% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
DOVA: -521.68
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -698.04, Med: -698.04, Max: -521.68
Current: -521.68
-698.04
-521.68
ROE % -79.90
ROE ranked lower than
66.23% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
DOVA: -79.9
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -105.11, Med: -96.62, Max: -79.9
Current: -79.9
-105.11
-79.9
ROA % -61.08
ROA ranked lower than
62.92% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
DOVA: -61.08
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -69.32, Med: -58.6, Max: -47.88
Current: -61.08
-69.32
-47.88
ROC (Joel Greenblatt) % -25076.71
ROC (Joel Greenblatt) ranked lower than
95.37% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
DOVA: -25076.71
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -92654.84, Med: -62932.61, Max: -25076.71
Current: -25076.71
-92654.84
-25076.71

» DOVA's 30-Y Financials

Financials (Next Earnings Date: 2019-08-09)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:DOVA

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare SZSE:300363 XSWX:BSLN BOM:540701 NAS:ALDR TPE:6541 NAS:VNDA TSX:PLI NAS:MNLO NAS:QURE NAS:ANIK NAS:JNCE TSE:2931 OSTO:RECI B NAS:CERS NAS:CBAY XKRX:096530 NAS:ECYT ROCO:4162 NAS:IFRX NAS:ADRO
Traded in other countries 0AV.Germany
Address 240 Leigh Farm Road, Suite 245, Durham, NC, USA, 27707
Dova Pharmaceuticals Inc is a United States based clinical-stage pharmaceutical company engaged in developing treatments for patients suffering from orphan diseases. It is focused on acquiring, developing and commercializing drug candidates for diseases that are treated by specialist physicians, with an initial focus on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. The company's drug candidate, avatrombopag, is an orally administered thrombopoietin receptor agonist, or TPO-RA, that it is developing for the treatment of thrombocytopenia. The company's drug candidate, avatrombopag, is designed to mimic the effects of thrombopoietin, in vitro and in vivo. Thrombopoietin is a hormone produced in the liver and kidney that binds to its receptor.

Ratios

Current vs industry vs history
PB Ratio 4.07
PB Ratio ranked lower than
54.68% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
DOVA: 4.07
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 2.51, Med: 4.8, Max: 8.19
Current: 4.07
2.51
8.19
PS Ratio 17.96
PS Ratio ranked lower than
100.00% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
DOVA: 17.96
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 15, Med: 40.24, Max: 195.4
Current: 17.96
15
195.4
EV-to-EBIT -2.61
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
DOVA: -2.61
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -15.4, Med: -4.8, Max: -1.5
Current: -2.61
-15.4
-1.5
EV-to-EBITDA -2.61
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
DOVA: -2.61
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -15.4, Med: -4.8, Max: -1.5
Current: -2.61
-15.4
-1.5
EV-to-Revenue 12.99
EV-to-Revenue ranked lower than
100.00% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
DOVA: 12.99
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 10, Med: 32.2, Max: 170.9
Current: 12.99
10
170.9
Current Ratio 4.46
Current Ratio ranked higher than
97.11% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
DOVA: 4.46
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.83, Med: 3.96, Max: 35.24
Current: 4.46
0.83
35.24
Quick Ratio 4.27
Quick Ratio ranked higher than
97.11% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
DOVA: 4.27
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.83, Med: 3.87, Max: 35.24
Current: 4.27
0.83
35.24
Days Inventory 475.64
Days Inventory ranked lower than
100.00% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
DOVA: 475.64
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 475.64, Med: 678.96, Max: 678.96
Current: 475.64
475.64
678.96
Days Sales Outstanding 5.72
Days Sales Outstanding ranked lower than
100.00% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
DOVA: 5.72
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 5.72, Med: 21.57, Max: 21.57
Current: 5.72
5.72
21.57
Days Payable 100.78
Days Payable ranked lower than
100.00% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
DOVA: 100.78
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 100.78, Med: 241.58, Max: 241.58
Current: 100.78
100.78
241.58

Dividend & Buy Back

Current vs industry vs history

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 4.08
Price-to-Tangible-Book ranked higher than
53.47% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
DOVA: 4.08
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 2.8, Med: 6.28, Max: 12.08
Current: 4.08
2.8
12.08
Price-to-Median-PS-Value 0.45
Price-to-Median-PS-Value ranked lower than
100.00% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
DOVA: 0.45
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.29, Med: 0.86, Max: 3.18
Current: 0.45
0.29
3.18
Earnings Yield (Joel Greenblatt) % -38.85
Earnings Yield (Greenblatt) ranked higher than
50.23% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
DOVA: -38.85
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -65.1, Med: -21, Max: -6.5
Current: -38.85
-65.1
-6.5

More Statistics

Revenue (TTM) (Mil) $ 14.36
EPS (TTM) $ -2.66
Beta 0
Volatility % 78.65
52-Week Range $ 5.62 - 35.33
Shares Outstanding (Mil) 28.23

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y